Canine Leptospirosis Market Size & Share, by Drug Type (Doxycycline, Penicillin, Ampicillin, Pfizerpen); Route of Administration (Oral, Intravenous); Distribution Channel (Veterinary Hospital Pharmacies, Veterinary Clinics, Retail Pharmacies, Drugstores, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5469
  • Published Date: Dec 22, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Canine Leptospirosis Market size is expected to reach USD 6 Billion by the end of 2036, expanding around 6% CAGR during the forecast period i.e., 2024-2036. In the year 2023, the industry size of canine leptospirosis was over 900 Million. The growth of this market can be primarily driven by the increased prevalence of infectious leptospirosis globally. Furthermore, the increasing transfer of infection from animals to humans is boosting the growth of the market. A study published in the journal Pathogen in March 2022 found that leptospirosis infection in humans is one of the leading and neglected causes of morbidity and mortality, with more than 1 million cases per year and approximately 60,000 people being found dead.

The global pet ownership is on the rise, with more and more people welcoming dogs into their families. This expanding pet population spreads to a larger pool of potential candidates for leptospirosis vaccination and treatment as a result driving the market growth of the canine leptospirosis market in the projected time period.


Canine Leptospirosis Market
Get more information on this report: Request Free Sample PDF


Canine Leptospirosis Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

~6%

Base Year Market Size (2023)

~USD 900 Million

Forecast Year Market Size (2036)

~USD 6 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Canine Leptospirosis Market: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Increasing Awareness by Government - Government authorities of various regions increasingly spreading awareness about canine leptospirosis this is a significant factor driving the growth of the canine leptospirosis market. For instance, In India, an initiative regarding named the National Program for Control and Prevention of Leptospirosis was formed. Increased awareness among pet owners and veterinarians regarding the risks associated with canine leptospirosis is accelerating the growth of the market. Educational campaigns by government authorities, veterinary organizations, and animal health companies are playing a crucial role in spreading awareness about the disease and its prevention.
  • Emergence of Lates and Multivalent Vaccines - The development of new and more effective vaccines, comprising multivalent vaccines that offer protection against multiple strains og bactericides, is another factor driving canine leptospirosis market growth. These vaccines provide broader protection and are often preferred by veterinarians and pet owners.
  • Growing Research and Development Activities - The increasing number of research and development activities taking place initiated by biopharmaceutical companies is boosting the market expansion of canine leptospirosis. For example, in December 2021, a New Zealand Health Research Council Research Project Grant awarded USD 0.61 million to Professor Jackie Benschop of the School of Veterinary Science.  
  • Impact of COVID-19 Pandemic - The COVID-19 pandemic initially had a significant impact on the leptospirosis market as diagnosis and treatment of various non-coronavirus diseases, including leptospirosis infections, were temporarily suspended or delayed. However, several countries reported an increase in leptospirosis cases during the epidemic. Such as a study published in the Journal of Medical Virology in September 2022 said that leptospirosis and coronavirus infections became endemic in coastal areas of southern India during the pandemic. Although the number of COVID-19 infections declined in the post-pandemic period, this led to the resumption of canine leptospirosis treatment and allowed the canine leptospirosis market to maintain its normal growth pace.

Challenges

  • Strict Regulatory Standards - The growth of the market for canine leptospirosis is expected to be hampered by a restrictive regulatory procedure in drug approvals. The challenge for market growth in the area of canine leptospirosis is a reduced diagnosis rate.
  • Environmental Concerns Associated with Canine Leptospirosis are also Predicted to hamper the Market Growth by the End of 2036.
  • The High Cost of Treatment and Vaccine in Canine Leptospirosis is Set to Pose a Limitation on the Market Expansion in the Upcoming Period


Canine Leptospirosis Segmentation

By Drug Type (Doxycycline, Penicillin, Ampicillin, Pfizerpen)

Based on drug type, the penicillin segment is predicted to dominate the canine leptospirosis market by registering a CAGR of 40% by the end of 2036. The segment growth in the forecast period is supported by the benefits of penicillin treatment over alternative treatments, as well as growing availability on the market. In research studies conducted, the effectiveness of penicillin against leptospirosis infection was considered to be highly effective and is expected to bring about greater awareness among patients as well as increased use of penicillin for the management of leptospirosis infections in order to support segment growth. In particular, early penicillin therapy appears to be effective and can minimize the risk of multiple organ failure as a result of leptospirosis by up to 80 % according to research presented at Membrane in March 2022.

Distribution Channel (Veterinary Hospital Pharmacies, Veterinary Clinics, Retail Pharmacies, Drugstores, Online Pharmacies)

Canine leptospirosis market from the veterinary hospital pharmacies segment is predicted to hold the highest revenue growth of 40% by the end of 2036. Collaboration between vet hospitals and pharmaceutical companies could facilitate research and development of innovative leptospirosis vaccines and therapeutics, ultimately benefitting the market.  Furthermore, the integration of technology solutions such as inventory management systems, and electronic health records can streamline operations, enhance inventory visibility, and personalize recommendations for pet owners, enhancing the overall pharmacy experience. Besides, veterinarians can directly recommend and dispense suitable antibiotics and supportive medications for diagnosed cases, ensuring quick treatment initiation. Also, veterinary hospitals can maintain optimal inventory levels of commonly used leptospirosis medications, ensuring immediate availability for their patients. Additionally, veterinary pharmacists can provide additional information and guidance to pet owners on medication administration, side effects, and follow-up care. All these are the significant factors considered behind the segment growth of veterinary hospital pharmacies in the market in the studied period.

Our in-depth analysis of the global canine leptospirosis market includes the following segments:

          Drug Type

  • Doxycycline
  • Penicillin
  • Ampicillin
  • Pfizerpen

          Route of Administration

  • Oral
  • Intravenous

          Distribution Channel

  • Veterinary Hospital Pharmacies
  • Veterinary Clinics
  •  Retail Pharmacies
  •  Drugstores
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Canine Leptospirosis Industry - Regional Synopsis

North American Market Forecasts

The canine leptospirosis market in the North America region is set to hold the largest market share of 35% by the end of 2036. Regional market growth has been projected to be boosted by the presence of drug manufacturers. There are also important animals in the region that have been linked to the zoonotic disease of leptospirosis. This will result in more demand for leptospirosis diagnosis and treatment, stimulating the development of the region's market. Indeed, in the U.S. between 63 % and 66 % of households representing 86.9 million homes had a pet as of 2023 according to estimates provided by the American Pet Products Association 2024. Furthermore, according to Pet Keen's data of May 2023, Canada has the biggest proportion of cat and dog owners in all developed countries with cats accounting for over 38% of households and dogs around 35%.

Europe Market Statistics

The canine leptospirosis market in the Europe region is set to hold a significant revenue share during the time period between 2024-2036. The growth of this market in the region can be attributed on the back of increasing investment in research and development activities. Furthermore, growing urbanization leads to increased contact between dogs and potential sources of leptospirosis bacteria, such as rats and contaminated water. Climate change and extreme events such as floods can also exacerbate the spread of the bacteria, creating new vulnerabilities for canine populations. This is set to accelerate the market growth in this region in the review period.  

Research Nester
Canine Leptospirosis Market Size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Canine Leptospirosis Market

top-features-companies
    • Pfizer Inc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Baxter International Inc.
    • Zoetic Pharmaceuticals Private Limited
    • Boehringer Ingelheim International GmbH
    • Sun Pharmaceuticals Industries Ltd
    • Aurobindo Pharma
    •  King Pharmaceuticals
    • Hikma Pharmaceuticals PLC
    • Mylab Discovery Solutions
    • Fresenius Kabi USA

In-the-news

In The News

  • In July 2022, Mylab Discovery Solutions launched  a comprehensive multiplex RT-PCR test kit for all monsoon diseases including malaria, chikungunya, dengue, Zika, leptospirosis, salmonellosis species and leishmaniasis. "PathoDetect Extended Monsoon Thermal Panel" has been released Parasite.
  •  In April 2022, as the monsoon period increases the risk of leptospirosis, India's Ministry of Health launched the 'Mritiunjayam' campaign in Kerela  to raise awareness about the disease.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5469
  • Published Date: Dec 22, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing expansion of the pet population and high prevalence of leptospirosis are some of the major factors anticipated to drive the growth of the canine leptospirosis market.

The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2024-2036

The major players in the market are of Baxter International Inc., Zoetic Pharmaceuticals Private Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceuticals Industries Ltd, Aurobindo Pharma, King Pharmaceuticals, and others.

The veterinary hospital pharmacies segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Canine Leptospirosis Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying